Patent Due Diligence: What Investors, Acquirers, and Partners Look For

At some point in every commercially successful invention's lifecycle, someone from outside will examine your patent portfolio under a microscope. An investor conducting due diligence before a funding round. An acquirer evaluating your company for purchase. A corporate partner assessing whether to enter a joint development or licensing arrangement. A licensee verifying that what you are offering to license is actually yours to license.

What they find — and what they do not find — determines whether the deal closes, at what valuation, and on what terms. Patent due diligence failures kill more deals than bad technology does, because a patent portfolio with defects creates legal risk that no investor or acquirer will accept.

This guide covers what due diligence examiners look for, how to prepare your portfolio to survive scrutiny, and the specific defects that derail deals.

The Hard Truth About Patent Due Diligence

Most independent inventors and early-stage startups fail their first due diligence review. Not because their patents are bad — but because the administrative foundations were never properly laid.

The three most common deal-killing defects:

Broken chain of title. The patent was filed in the inventor's personal name but was never formally assigned to the company. Or a co-inventor signed an employment agreement but not an IP assignment. Or a contractor contributed to the invention without signing an IP assignment clause. In each case, the company that claims to own the patent does not — or cannot prove that it does — and the investor discovers this during due diligence.

Undisclosed encumbrances. An existing licence was granted years ago and never documented properly. A prior employer has a potential claim under an employment agreement the founder forgot about. A co-inventor who left the company retains ownership rights that were never addressed. These encumbrances reduce the patent's value and may make it unlicensable or unenforceable.

Lapsed maintenance. A patent that was allowed to lapse due to missed maintenance fees — even temporarily — creates a period during which competitors could have entered the market. Revival is usually possible, but the lapse is a red flag that suggests the portfolio has not been actively managed.

All three are preventable with basic IP hygiene. The time to fix them is now — not the week before a term sheet closes.

The Due Diligence Checklist

1. Chain of Title

The examiner traces ownership from the original inventor(s) through every transfer to the current owner. Every link in the chain must be documented and recorded.

What they check:

• Inventor declarations — are all named inventors correctly identified?
• Assignment agreements — is there a signed, dated assignment from each inventor to the company?
• Recordation — has each assignment been recorded at the relevant patent office (USPTO Assignment Division, EPO, CNIPA, etc.)?
• Contractor and employee IP assignments — does the company have signed IP assignment agreements from every person who contributed to the invention?
• University or prior employer claims — did any inventor develop any aspect of the invention while employed elsewhere or while affiliated with a university? If so, has the prior institution's claim been addressed?

The fix: Execute assignment agreements with every inventor and contributor. Record them at every patent office where the patent is registered. If an inventor has left the company and did not sign an assignment, this is an urgent problem — reach out immediately and resolve it before due diligence begins.

2. Patent Portfolio Inventory

A complete, accurate list of every patent and patent application in the portfolio, with current status.

What they check (for each patent/application):

The fix: Maintain a portfolio spreadsheet (or use a patent management tool) with every field above, updated at least quarterly. Verify maintenance fee status before any due diligence review.

3. Validity Assessment

The examiner assesses whether the patents are likely to survive a validity challenge.

What they check:

• Was the patent substantively examined? (A South African depository patent or an unexamined utility model carries weaker presumptive validity than a USPTO or EPO-examined patent)
• Is there known prior art that was not cited during prosecution?
• Were claims significantly narrowed during prosecution? (Extensive narrowing suggests the examiner found substantial prior art)
• Has the patent survived any post-grant challenge (IPR, opposition, invalidity action)? (Survival substantially increases value)
• Are there pending validity challenges?

What reduces confidence: Multiple rounds of prosecution with significant claim amendments. Prior art that closely anticipates the granted claims. A prosecution history filled with arguments that limit claim scope through estoppel.

What increases confidence: Clean prosecution with minimal amendments. A positive international search report. Survival of an IPR or opposition challenge. Multiple independent claims covering different aspects of the invention.

4. Freedom to Operate

The examiner assesses whether the company's products — not just its patents — are free from third-party patent risk.

What they check:

• Has an FTO analysis been conducted for each commercial product?
• Are there identified third-party patents that may be infringed?
• Are there existing licences from third parties that address FTO risks?
• Are there pending infringement claims or threats?

An investor is buying into a business, not just a patent portfolio. If the business's products infringe someone else's patents, the investor inherits that liability. See: Freedom to Operate: What It Is and Why It Matters

5. Encumbrances and Existing Licences

What they check:

• Are there existing licences granted to third parties? (If so: exclusive or non-exclusive? What territory? What field? What royalty terms? What termination provisions?)
• Are there liens, security interests, or pledges against the patents?
• Are there co-ownership arrangements with third parties?
• Are there grant-back obligations from prior licensing that affect the patents?
• Are there government-funded research obligations (Bayh-Dole in the US, equivalent provisions elsewhere) that give the government march-in rights?

The fix: Compile a complete register of every encumbrance, licence, and obligation attached to every patent in the portfolio. Disclose everything proactively — undisclosed encumbrances discovered during due diligence are deal-killers not because of their substance but because of the concealment.

6. Commercial Value Assessment

Beyond legal validity, the examiner assesses whether the patents have commercial value.

What they check:

• Do the patents cover the company's actual products and revenue streams?
• Do the claims cover competitor products? (Enforcement value)
• What is the remaining patent term? (A patent with 3 years remaining is worth far less than one with 15 years)
• Are the claims broad enough to prevent design-around?
• Is the technology area growing or declining?
• Are there continuation applications pending that could expand coverage?

Preparing for Due Diligence: The 30-Day Sprint

If you know due diligence is coming (a funding round, an acquisition discussion, a major licensing deal), here is what to do in the 30 days before it begins:

Week 1: Compile the portfolio inventory. Verify every patent number, filing date, grant date, and maintenance fee status. Fix any discrepancies.

Week 2: Verify chain of title. Confirm that signed assignment agreements exist for every inventor and contributor. Record any unrecorded assignments at each patent office. If any assignment is missing, execute it immediately.

Week 3: Review prosecution histories. Flag any patents where claims were significantly narrowed or where arguments made during prosecution could limit scope. Prepare a brief summary of each patent's prosecution history highlighting key amendments and their rationale.

Week 4: Compile the encumbrance register. Document every existing licence, obligation, lien, and co-ownership arrangement. Prepare a clean summary disclosing all encumbrances.

Throughout: Ensure maintenance fees are current in every jurisdiction. A lapsed patent discovered during due diligence — even if revivable — signals poor portfolio management and erodes confidence.

Red Flags That Kill Deals

Missing inventor assignments. If the founding inventor never assigned their patent to the company, the company does not own its core IP. This is the single most common due diligence failure in early-stage companies.

Undisclosed prior employer claims. A founder who left a large company to start a venture, and whose employment agreement contains a broad IP assignment clause covering inventions "related to the employer's business," creates a potential claim that investors cannot ignore.

Lapsed patents in key jurisdictions. Discovering that the Chinese patent lapsed 18 months ago because no one was tracking renewal fees raises questions about what else in the portfolio has been neglected.

Prosecution history estoppel that guts the claims. A patent whose independent claims were amended three times during prosecution — each time adding narrowing limitations — may have claims so narrow that competitors can design around them trivially. The due diligence examiner reads the prosecution history specifically to assess this risk.

No FTO analysis. A company that has never conducted a freedom-to-operate analysis for its commercial products is asking investors to accept unknown infringement risk. Most sophisticated investors will require an FTO opinion as a condition of closing.

Unrealistic patent valuation. An inventor who values their patent portfolio at $50M based on theoretical market potential, when comparable transactions suggest $500K–$2M, creates a valuation gap that may prevent the deal from closing at any price.

Sources

1. USPTO - Assignment Recording — Verify patent ownership chain of title and recorded assignments
2. USPTO Patent Center — Access prosecution histories, maintenance fee status, and application status for due diligence review
3. Espacenet — Verify European and international patent family status, validation, and maintenance
4. WIPO - IP for Business — Guidance on IP valuation and due diligence frameworks for investors and partners
5. Lens.org — Open patent and scholarly data platform for analysing citation networks and patent families